159 related articles for article (PubMed ID: 28178660)
1. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Koncar RF; Chu Z; Romick-Rosendale LE; Wells SI; Chan TA; Qi X; Bahassi EM
Oncotarget; 2017 Feb; 8(9):15827-15837. PubMed ID: 28178660
[TBL] [Abstract][Full Text] [Related]
2. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
3. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
4. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Liu N; Hu G; Wang H; Li Z; Guo Z
J Cell Mol Med; 2018 Nov; 22(11):5300-5310. PubMed ID: 30133120
[TBL] [Abstract][Full Text] [Related]
5. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
7. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Shen Y; Li J; Nitta M; Futalan D; Steed T; Treiber JM; Taich Z; Stevens D; Wykosky J; Chen HZ; Carter BS; Becher OJ; Kennedy R; Esashi F; Sarkaria JN; Furnari FB; Cavenee WK; Desai A; Chen CC
Oncotarget; 2015 May; 6(14):11751-67. PubMed ID: 26059434
[TBL] [Abstract][Full Text] [Related]
8. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
Tateishi K; Higuchi F; Miller JJ; Koerner MVA; Lelic N; Shankar GM; Tanaka S; Fisher DE; Batchelor TT; Iafrate AJ; Wakimoto H; Chi AS; Cahill DP
Cancer Res; 2017 Aug; 77(15):4102-4115. PubMed ID: 28625978
[No Abstract] [Full Text] [Related]
9. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Wang JB; Dong DF; Wang MD; Gao K
Asian Pac J Cancer Prev; 2014; 15(1):427-32. PubMed ID: 24528069
[TBL] [Abstract][Full Text] [Related]
10. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
[TBL] [Abstract][Full Text] [Related]
11. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Ohba S; Mukherjee J; See WL; Pieper RO
Cancer Res; 2014 Sep; 74(17):4836-44. PubMed ID: 25035396
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Lu Y; Kwintkiewicz J; Liu Y; Tech K; Frady LN; Su YT; Bautista W; Moon SI; MacDonald J; Ewend MG; Gilbert MR; Yang C; Wu J
Cancer Res; 2017 Apr; 77(7):1709-1718. PubMed ID: 28202508
[TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
[TBL] [Abstract][Full Text] [Related]
15. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Momota H; Nerio E; Holland EC
Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
[TBL] [Abstract][Full Text] [Related]
16. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
[TBL] [Abstract][Full Text] [Related]
17. PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.
Lund-Andersen C; Patzke S; Nähse-Kumpf V; Syljuåsen RG
Radiother Oncol; 2014 Feb; 110(2):355-61. PubMed ID: 24502970
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
19. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Tsuno T; Natsume A; Katsumata S; Mizuno M; Fujita M; Osawa H; Nakahara N; Wakabayashi T; Satoh Y; Inagaki M; Yoshida J
J Neurooncol; 2007 Jul; 83(3):249-58. PubMed ID: 17570035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
